Product Information
VERAPAMIL ER 180 MG CAPSULE is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $2.0866 per EA under NDC 00378638001. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Apr 20, 1999. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
180 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378638001
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
VERAPAMIL HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA075138FDA Approved
4/20/1999
TE Code
AB
On Market Since
5/20/1999
Pharmacological Classes
Price Statistics
The NADAC for VERAPAMIL ER 180 MG CAPSULE has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 265.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.0866 per EA |
|---|---|
| All-time high | $2.2961 (Mar 11, 2026) |
| All-time low | $0.4773 (Feb 18, 2015) |
| 52-week high | $2.2961 |
| 52-week low | $1.0471 |
| Median price | $1.1583 |
| Average price | $1.1289 |
| Largest weekly change | +47.4% (Sep 23, 2026) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 50% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
verapamil hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcium Channel Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VERAPAMIL ER 180 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for VERAPAMIL ER 180 MG CAPSULE, manufactured by Mylan Pharmaceuticals Inc., is $2.0866 per EA (NDC 00378638001), effective Sep 30, 2026.
How has the price of VERAPAMIL ER 180 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for VERAPAMIL ER 180 MG CAPSULE has risen 265.1%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for VERAPAMIL ER 180 MG CAPSULE?
Since Nov 28, 2013, the NADAC for VERAPAMIL ER 180 MG CAPSULE has ranged from a low of $0.4773 (Feb 18, 2015) to a high of $2.2961 (Mar 11, 2026), with a median of $1.1583 per EA.
Are there cheaper alternatives to VERAPAMIL ER 180 MG CAPSULE?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, VERAPAMIL SR 180 MG CAPSULE, is $1.0471 per EA — about 50% below VERAPAMIL ER 180 MG CAPSULE.
Who manufactures VERAPAMIL ER 180 MG CAPSULE?
VERAPAMIL ER 180 MG CAPSULE (NDC 00378638001) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.